defibrillator implant Articles
-
Executive Agency for Small & Medium-sized Enterprises (EASME) SME Instrument - European R&D Framework Program Horizon 2020 - Case Study
NewPace develops and patented the Implantable Subcutaneous String Defibrillator (ISSD™) which is the first, completely unitary and flexible, rechargeable, lifesaving implanted defibrillator. Its innovative, minimally invasive, shape introduces a new dimension in subcutaneous cardioverter ...
By NewPace Ltd.
-
A less invasive approach to treating sudden cardiac arrest
Sudden cardiac arrest (SCA), a life-threatening emergency that occurs when the heart suddenly stops beating, is a leading cause of death throughout the developed world. As its name suggests, SCA happens suddenly and with little warning. As a result, out of the nearly 350 000 European lives that SCA claims every year, 95 % die before they reach the hospital. The only accepted method for treating ...
By NewPace Ltd.
-
Novel String-Shaped Subcutaneous ICD Proves Effective in Patients
May 16, 2017 – A new study examines the effectiveness of the implantable subcutaneous string defibrillator (ISSD), a flexible, string-shaped and first-ever rechargeable implantable cardioverter-defibrillator (ICD). This is the first-in-man study to report on the feasibility of the innovative device and was presented today at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual ...
By NewPace Ltd.
-
HRS 2017: New implantable string subcutaneous defibrillator shows promise for sudden cardiac death prevention
The use of a novel implantable string subcutaneous defibrillator (ISSD, Newpace) that has no can, and has been designed to be placed without the need for a surgical pocket, may allow improved patient compliance and aesthetics, is less invasive, and has optimal implantation time. The results from a first-in-man feasibility study on subcutaneous defibrillation utilising an integrated flexible ...
By NewPace Ltd.
-
Rani Therapeutics’ $73M IPO will fund upcoming clinical trials
Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday. According to S-1 filings, shares were estimated to price between $14 and $16 last week. On Friday, shares debuted slightly lower, around $11. Rani raised about $73 million in its debut. Rani’s debut comes amidst a flurry of IPO activity in therapeutics. In 2020, 71 ...
-
An introduction to Congenital Heart Defects
An estimated 2.4 million American children and adults are currently living with congenital heart defects (CHDs). Learn more about different types of CHDs, causes and treatment options. Learning that your child has a CHD can be a scary and overwhelming experience, but it’s important to know that you’re not alone. Nearly 40,000 infants in the U.S. are born each year with CHDs, and ...
-
Baroreflex Activation Therapy: A Novel Approach for HFrEF Patients
During the webinar, you’ll learn about: Treatment options and unmet needs of HFrEF patients The physiologic rationale of baroreflex activation Barostim therapy overview and clinical evidence overview Appropriate patient selection and real-world experience Important Safety Information CAUTION: Federal law restricts this device to sale by or on the ...
By CVRx
-
First-in-man demonstration of 18-month spatiotemporal stability of active atrial fibrillation source detected by Electrographic Flow mapping in persistent atrial fibrillation
Keywords: atrial fibrillation, catheter ablation, mapping, atrial fibrillation, source, electrographic flow Introduction: Advanced mapping methods for atrial fibrillation (AF) have previously suffered from poor spatiotemporal stability. Electrographic flow (EGF) mapping is a novel technique using computer vision and optical flow smoothing algorithms to avoid this issue. The aim of this ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you